Logo image
Back
Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis
Journal article   Peer reviewed

Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis

Yuting Kuang, Christine M Pierce, Hsiu-Ching Chang, Alexandra Z Sosinsky, Anne C Deitz, Steven M Keller, Ayman Samkari and Jennifer Uyei
Lung cancer (Amsterdam, Netherlands), v 174, 174
01 Dec 2022
DOI: https://doi.org/10.1016/j.lungcan.2022.06.005
PMID: 35717343
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Carcinoma, Non-Small-Cell Lung - therapy Chemoradiotherapy - adverse effects Chemoradiotherapy - methods Humans Lung Neoplasms - therapy Pneumonia - chemically induced Pneumonia - etiology Radiation Pneumonitis - diagnosis Radiation Pneumonitis - epidemiology Radiation Pneumonitis - etiology
High-grade pneumonitis is a severe and potentially life-threatening adverse event associated with concurrent chemoradiation (cCRT) in patients with non-small cell lung cancer (NSCLC). The aim of this study was to summarize and quantify the incidence of severe (grade 3-5) cCRT-induced pneumonitis in unresectable stage III NSCLC patients. A systematic literature review and meta-analysis were performed in accordance with PRISMA guidelines. Published literature was searched for randomized controlled trials (RCTs), observational studies, and non-randomized trials from 2014 to April 2020. The primary outcome of interest was incidence of grade 3-5 pneumonitis. Included were 17 studies for the review and 11 for the meta-analysis (1,788 participants); all studies examined radiation-related pneumonitis (RP). The pooled incidence of cCRT-induced grade 3-5 RP in unresectable stage III NSCLC patients was estimated to be 3.62% [95% confidence interval (CI): 1.65-6.21] in RCTs, 5.98% [95% CI: 2.26-12.91] in observational studies, and 7.85% [95% CI: 4.08-13.10] in observational studies using platinum-based doublet chemotherapies. These results suggest the incidence of severe and fatal RP in patients with unresectable stage III NSCLC treated with cCRT ranges from 3.62% to 7.85%, with incidence varying by study design and chemotherapy regimen. Estimates of RP incidence were higher in the real-world setting compared to RCTs. These results can be used to contextualize the baseline risk of cCRT-induced pneumonitis in unresectable stage III NSCLC to better understand the adverse event of pneumonitis associated with novel immunotherapy treatments indicated for concomitant use with this modality.

Metrics

25 Record Views
26 citations in Web of Science
22 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Oncology
Respiratory System
Logo image